Saleem Mahammad

Saleem Mahammad joined Renovaro in the role of Associate Director for Research and Development. He brings with him over ten years of experience from the biopharmaceutical industry and academia. With a solid foundation in immuno-oncology, and cancer therapeutics, Dr. Mahammad held numerous leadership and scientific positions before joining Renovaro Biosciences. As a group leader at Fusion Pharmaceuticals, he led proof-of-concept and MOA studies for small-molecule, antibody therapeutics targeting various cancer indications. His research led to the development of FPI-2059, a small molecule radio-conjugate to treat patients with advanced solid tumors that are positive for neurotensin receptor-1. His work at Fusion pharmaceuticals contributed to numerous patents and to the development of multiple programs into the clinic. He oversaw proof-of-concept and MOA studies at Turnstone Biologics to bring the next generation of viral immunotherapies to cancer patients. His noteworthy work in academia and industry has resulted in publications in top-tier journals and the development of multiple commercial products for the treatment of patients in clinical settings, ranging from neurological diseases to cancer therapies. He received Ph.D. in Immunology and Cell Biology from Stockholm University, Sweden, followed by post-doctoral training at Feinberg Medical School, Northwestern university, Chicago and at McMaster University, Hamilton, ON, Canada.

BACK